June 3, 2020 - The case was voluntarily dismissed.

November 26, 2019 - An investigation on behalf of investors of Aytu BioScience, Inc. (NASDAQ: AYTU) shares over potential securities laws violations by Aytu BioScience, Inc. and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Aytu BioScience, Inc. (NASDAQ: AYTU) concerning whether a series of statements by Aytu BioScience, Inc. (NASDAQ: AYTU regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Englewood, CO based Aytu BioScience, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), cough and upper respiratory symptoms, insomnia, and male infertility in the United States and internationally. Aytu BioScience, Inc. reported that its Total Revenue rose from $3.22 million for the 12 months period that ended on June 30, 2017 to $3.66 million for the 12 months period that ended on June 30, 2018 and that its Net Loss declined from $22.5 million to $10.18 million over those respective time periods.

Shares of Aytu BioScience, Inc. (NASDAQ: AYTU) declined from $2.47 per share in April 2019 to as low as $0.90 per share on November 8, 2019.